Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixekizumab dose-ranging in moderate-to-severe psoriasis
NCT01107457Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Apr 2010
- Primary completion
- Jan 2011
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of ixekizumab in plaque psoriasis (5 arms), sponsored by Eli Lilly and Company. Primary endpoints: Percentage of Participants Achieving Psoriasis Area and Severity Index ≥75% Improvement at 12 weeks and Percentage of PASI Improvement From Baseline at 12 weeks. Started Apr 2010; status: completed.
02
Drugs
ixekizumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT01107457.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01107457.